The levonorgestrel intrauterine system versus endometrial ablation for heavy menstrual bleeding: a cost‐effectiveness analysis. (27th July 2021)

• Record Type: Journal Article
• Authors: van den Brink, MJ; Beelen, P; Herman, MC; Geomini, PM; Dekker, JH; Vermeulen, KM; Bongers, MY; Berger, MY
• Is Part Of: BJOG. Volume 128:Number 12(2021)
• Page Start: 2003
• Page End: 2011
• Publication Date: 2021-07-27
• Subjects: Cost‐effective analysis -- economic evaluation -- excessive uterine bleeding -- intrauterine device -- menorrhagia -- menstruation -- mirena -- noninferiority trial -- novasure; Obstetrics -- Periodicals; Gynecology -- Periodicals; 618
• DOI: 10.1111/1471-0528.16836
• Languages: English
• ISSNs: 1470-0328

Abstract

Abstract : Objective: To evaluate the costs and non‐inferiority of a strategy starting with the levonorgestrel intrauterine system (LNG‐IUS) compared with endometrial ablation (EA) in the treatment of heavy menstrual bleeding (HMB). Design: Cost‐effectiveness analysis from a societal perspective alongside a multicentre randomised non‐inferiority trial. Setting: General practices and gynaecology departments in the Netherlands. Population: In all, 270 women with HMB, aged ≥34 years old, without intracavitary pathology or wish for a future child. Methods: Randomisation to a strategy starting with the LNG‐IUS ( n = 132) or EA ( n = 138). The incremental cost‐effectiveness ratio was estimated. Main outcome measures: Direct medical costs and (in)direct non‐medical costs were calculated. The primary outcome was menstrual blood loss after 24 months, measured with the mean Pictorial Blood Assessment Chart (PBAC)‐score (non‐inferiority margin 25 points). A secondary outcome was successful blood loss reduction (PBAC‐score ≤75 points). Results: Total costs per patient were €2, 285 in the LNG‐IUS strategy and €3, 465 in the EA strategy (difference: €1, 180). At 24 months, mean PBAC‐scores were 64.8 in the LNG‐IUS group ( n = 115) and 14.2 in the EA group ( n = 132); difference 50.5 points (95% CI 4.3–96.7). In the LNG‐IUS group, 87% of women had a PBAC‐score ≤75 points versus 94% in the EA group (relative risk [RR] 0.93, 95% CI 0.85–1.01). The ICER was €23 (95% CI €5–111) per PBAC‐point. Conclusions: A strategy starting with the LNG‐IUS was cheaper than starting with EA, but non‐inferiority could not be demonstrated. The LNG‐IUS is reversible and less invasive and can be a cost‐effective treatment option, depending on the success rate women are willing to accept. Tweetable abstract: Treatment of heavy menstrual bleeding starting with LNG‐IUS is cheaper but slightly less effective than endometrial ablation. Tweetable abstract: Treatment of heavy menstrual bleeding starting with LNG‐IUS is cheaper but slightly less effective than endometrial ablation.